Phase I/II study of the oral HIF-2 alpha inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)-MedSci.cn

Phase I/II study of the oral HIF-2 alpha inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC)

Choueiri, TK; Plimack, ER; Bauer, TM; Merchan, JR; Papadopoulos, KP; McDermott, DF; Michaelson, MD; Appleman, LJ; Thamake, S; Zojwalla, NJ; Jonasch, E

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (6):

科室
- - 订阅+
  - 更多科室
工具
服务